- LogicBio to receive $10M up front with ~$581M as option payment and milestones along with royalties. Canbridge to get an exclusive option to license LB-001 in Greater China and two additional undisclosed gene therapy programs.
- The agreement also grants CANbridge a WW license for AAV sL65 which is the first capsid produced from LogicBio’s sAAVy platform, and development support on gene therapy candidates for Fabry and Pompe disease + two optional indications
- Canbridge will responsible for the development, regulatory, commercial, and manufacturing activities in the licensed territory upon exercise of an option
Click here to read full press release/ article | Ref: PRNewswire | Image: LogicBio
The post LogicBio Signs an Option Agreement with Canbridge to Develop Gene Editing Therapies first appeared on PharmaShots.